Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
SPRY Stock Chart & Stats
$10.14
-$0.02(-0.18%)
At close: 4:00 PM EST
$10.14
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$6.66 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.50M
Market Cap
$1.00B
Enterprise Value$944.30M
Total Cash (Recent Filing)$288.21M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 19, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding98,848,610
10 Day Avg. Volume1,464,873
30 Day Avg. Volume1,498,372
Financial Highlights & Ratios
PEG Ratio-1.12
Price to Book (P/B)3.98
Price to Sales (P/S)11.47
P/FCF Ratio78.76
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue6.61
Enterprise Value/Gross Profit7.76
Enterprise Value/Ebitda-11.37
Forecast
1Y Price Target
$32.50Price Target Upside220.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.38
Revenue Forecast (FY)$172.77M
Bulls Say, Bears Say
Bulls Say
Commercial MomentumExpansion of the neffy prescriber base and stronger-than-expected U.S. sales indicate growing adoption that could translate into higher prescriptions and revenue as commercial programs scale.
Product Tolerability And First-mover AdvantageNeffy's favorable tolerability profile and status as the only needle-free epinephrine device in the market support potential share gains versus competitors reporting higher oral adverse events.
Regulatory Setback For CompetitorFDA's complete response letter for a rival cited administration and labeling deficiencies, likely delaying the rival's market entry and easing near-term competitive pressure on Ars Pharmaceuticals.
Bears Say
Regulatory Outcome UncertaintyRegulatory ambiguity remains because the regulator did not specify the deficiencies, leaving the final decision and any additional study requirements unclear and introducing potential delays or swings in competitive dynamics.
ARS Pharmaceuticals News
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $6.66 and its highest was $18.90 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $1.00B.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Mar 19, 2026 which is in 41 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.454 by -$0.066.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.43.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 98,848,610 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.454. Following the earnings report the stock price went up 0.339%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.50 (220.51% Upside)
$32.50 (220.51% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.00%
12-Months-Change
Fundamentals
Return on Equity
-45.92%
Trailing 12-Months
Asset Growth
71.32%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Company Deck
SPRY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant revenue growth and strategic initiatives like the 'Get Nephi On Us' program and global expansion. However, challenges such as temporary pauses in market share growth, data inaccuracies, and expected Q4 sales decline were noted.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$32.50
▲(220.51% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---